Trial Profile
Phase Ia first-in-human study of XmAb 5871 in healthy adult men.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Obexelimab (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions
- 15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
- 13 Feb 2013 Status changed from recruiting to completed, based on a Xencor media release.
- 10 Mar 2011 New trial record